Brands
Trust to be integral part of CEO strategy in 2019: brand-comm summit
MUMBAI: Integrated brand-comm, a Madison Group company, recently hosted the brand-comm Summit 'The Journey from Attention to Trust' in Bengaluru where it was inferred that trust is the most relevant theme and objective of communications in 2019.
Accenture Solutions Pvt Ltd chairman and senior managing director Rekha Menon stated that there can be a significant impact on value to a company from any compromise of trust. This is proved by the impact of the loss of trust on the revenues of companies. “Of some 7,000 companies studied globally by Accenture, 54 per cent of these organisations experienced a drop in trust. This had led to a revenue loss of over USD 180 billion. Considering these, it is essential that trust be an integral part of the CEO strategy,” she said.
Speaking on the subject of need to build trust among consumers is integral to the success of any brand at the summit, Mindworks CEO R Gopalakrishnan said that when crisis hits, there is panic within the company and its board. Under such adverse circumstances, the role of the leader becomes integral in decision-making. However, such decisions need to be taken in sync with the DNA of the company.
But the idea of authenticity in communication did not hit mainstream till the end of the last millennium, said Madison World chairman and managing director Sam Balsara. He spoke on how his campaign to advocate the continuity of the Parsi community in India has actually led to an 18 per cent increase in the population of the community. While the role of advertising is to make the product look larger than what it is, it is essential that authenticity gain precedence in the messaging.
Integrated brand-comm CEO and founder Ramanujam Sridhar said that consumers have become discerning, which have led to polarisation of views. He added that consumers will become increasingly selective about what they want to see and hear in 2019.
Continuing with the theme of authenticity, AVTAR Group founder-president Soundarya Rajesh suggested that attention, consistency and authenticity are integral to each other. She added that inclusive communication is critical to the process of creating trust.
Community disseminated messaging on the social media has built a greater trust among the millennials and other target audiences, hence there is a need to influence this narrative that would be in line with the communication that a business wishes to convey. So, brands need to influence creating content that would influence user,” said Saundarya Rajesh.
Brands
Sun Pharma to acquire Organon in $11.75 billion deal at $14 per share
Acquisition to create $12.4 billion pharma giant with global scale and biosimilars push
MUMBAI: Sun Pharmaceutical Industries Limited has signed a definitive agreement to acquire Organon & Co. in an all-cash deal valued at $11.75 billion, marking one of the largest cross-border pharma acquisitions by an Indian firm.
Under the terms of the agreement, Organon shareholders will receive $14.00 per share in cash, with Sun Pharma set to acquire 100 per cent of the company’s outstanding shares. The transaction, approved by the boards of both companies, is expected to close in early 2027, subject to regulatory approvals and shareholder consent.
The deal significantly expands Sun Pharma’s global footprint and strengthens its position across women’s health, biosimilars, and branded generics. The combined entity is projected to generate revenues of around $12.4 billion, placing it among the top 25 pharmaceutical companies globally.
Organon, which was spun off from Merck in 2021, brings a portfolio of over 70 products spanning women’s health and general medicines, with operations across more than 140 countries. Its established presence in key markets such as the US, Europe, and China complements Sun Pharma’s existing strengths and growth ambitions.
Sun Pharmaceutical Industries Limited executive chairman Dilip Shanghvi said, “This transaction represents a significant opportunity for Sun Pharma to build on its vision of reaching people and touching lives. Organon’s portfolio, capabilities and global reach are highly complementary to our own.”
Sun Pharmaceutical Industries Limited managing director Kirti Ganorkar added, “This transaction is a logical next step in strengthening Sun Pharma’s global business. Together, we will become a partner of choice for acquiring and launching new products.”
From Organon’s side, Organon & Co. executive chair Carrie Cox noted, “This all-cash transaction offers compelling and immediate value to Organon stockholders, while positioning the business for continued growth under Sun Pharma.”
Strategically, the acquisition gives Sun Pharma entry into the global biosimilars space as a top 10 player and strengthens its innovative medicines portfolio, which is expected to contribute around 27 per cent of combined revenues. The deal is also expected to nearly double EBITDA and cash flow, supporting long-term deleveraging and investment capacity.
Sun Pharma plans to fund the acquisition through a mix of internal accruals and committed financing from global banks, while maintaining focus on disciplined integration and operational continuity post-merger.
If completed as planned, the deal signals a clear shift in India’s pharmaceutical ambitions, from scale at home to leadership on the global stage, with Sun Pharma positioning itself as a more diversified and innovation-led healthcare powerhouse.
